Search
01/04/2025
Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease.
Sivera Mascaró R, García Sobrino T, Horga Hernández A, Pelayo Negro AL, Alonso Jiménez A, Antelo Pose A, Calabria Gallego MD, Casasnovas C, Cemillán Fernández CA, Esteban Pérez J, Fenollar Cortés M, Frasquet Carrera M, Gallano Petit MP, Giménez Muñoz A, Gutiérrez Gutiérrez G, Gutiérrez Martínez A, Juntas Morales R, Ciano-Petersen NL, Martínez Ulloa PL, Mederer Hengstl S, Millet Sancho E, Navacerrada Barrero FJ, Navarrete Faubel FE, Pardo Fernández J, Pascual Pascual SI, Pérez Lucas J, Pino Mínguez J, Rabasa Pérez M, Sánchez González M, Sotoca J, Rodríguez Santiago B, Rojas García R, Turon-Sans J, Vicent Carsí V, Sevilla Mantecón T. Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease.. Neurologia. 2025; 40(3)DOI:10.1016/j.nrleng.2024.02.008. PMID:38431252. IF:(Q/D).
01/04/2025
New scoring balloon to treat moderate-to-severe calcified coronary lesions. The first-in-man Naviscore study
Peñaranda, AS, Peregrina, EF, Kockar, MJ, del Blanco, BG, Romani, S, Moreiras, JM, Bermúdez, EP, Rodrigues, A, Ojeda, S, López, NG, Regueiro, A, Frutos, AS. New scoring balloon to treat moderate-to-severe calcified coronary lesions. The first-in-man Naviscore study. REC, interventional cardiology. 2025; 7(2)DOI:10.24875/RECICE.M24000484. PMID:. IF:(Q/D).
01/04/2025
Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure
Anido-Varela, L, Aragón-Herrera, A, González-Maestro, A, Bellas, CT, Tarazón, E, Solé-González, E, Martínez-Sellés, M, Guerra-Ramos, JM, Carrasquer, A, Morán-Fernández, L, García-Vega, D, Seoane-Blanco, A, Moure-González, M, Seijas-Amigo, J, Rodríguez-Penas, D, García-Seara, J, Moraña-Fernández, S, Vázquez-Abuín, X, Roselló-Lletí, E, Portolés, M, Eiras, S, Agra, RM, Alvarez, E, González-Juanatey, JR, Feijóo-Bandín, S, Lago, F. Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2025; 55(4)DOI:10.1111/eci.14380. PMID:39834188. IF:3.600(Q1/2D).
01/04/2025
Geriatric conditions and invasive management in frail patients with NSTEMI. A subgroup analysis of a randomized clinical trial
Sanchis, J, Bueno, H, Garcia-Blas, S, Gomez-Hospital, JA, Marti, D, Martinez-Selles, M, Dominguez-Perez, L, Diez-Villanueva, P, Barrabes, JA, Marin, F, Villa, A, Sanmartin, M, Llibre, C, Sionis, A, Carol, A, Valero, E, Calvo, E, Morales, MJ, Elizaga, J, Gomez, I, Alfonso, F, del Blanco, BG, Formiga, F, Nunez, E, Nunez, J, Ariza-Sole, A. Geriatric conditions and invasive management in frail patients with NSTEMI. A subgroup analysis of a randomized clinical trial. REVISTA ESPANOLA DE CARDIOLOGIA. 2025; 78(4)DOI:10.1016/j.rec.2024.08.006. PMID:39270775. IF:4.900(Q1/2D).
01/04/2025
Peroral endoscopic myotomy (POEM) as a treatment for pediatric achalasia: multicenter study and first results
Villanueva, CL, Arbizu, EA, Goruppi, I, Lozano, NB, Bianchi, F, Martínez, AP, Pina, SM, Caballero, AYM, Murzi, M, Betroletti, F, Estremera, F, Guerrero, SB, Argente, CG. Peroral endoscopic myotomy (POEM) as a treatment for pediatric achalasia: multicenter study and first results. Gastroenterologia y Hepatologia. 2025; 48(4)DOI:10.1016/j.gastrohep.2024.502262. PMID:39343296. IF:1.900(Q3/7D).
01/04/2025
CNS manifestations in acute and chronic graft-versus-host disease
Lambert, N, Forte, F, El Moussaoui, M, Monseur, J, Raus, N, Polushin, A, Michonneau, D, Shultz, C, Hogan, WJ, Balaguer-Roselló, A, Gil-Perotín, S, Brijs, J, Chauvet, P, Gavriilaki, M, Carre, M, Dulamea, AO, Chalandon, Y, Salmenniemi, U, Duminuco, A, Ram, R, García-Cadenas, I, Porto, G, Nguyen, S, Smallbone, P, González-Vicent, M, Santoro, JD, Willems, E, Baron, F, Servais, S, Beguin, Y, Maquet, P. CNS manifestations in acute and chronic graft-versus-host disease. BRAIN. 2025; 148(4)DOI:10.1093/brain/awae340. PMID:39442000. IF:11.700(Q1/1D).
31/03/2025
Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction
Briones, AM, Hernanz, R, García-Redondo, AB, Rodriguez, C, Blanco-Colio, LM, Val-Blasco, A, Alonso, MJ, Salaices, M. Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2025; 136(5)DOI:10.1111/bcpt.70026. PMID:40159875. IF:3.300(Q2/4D).
30/03/2025
Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysis
Afferi, L, Jahn, B, Kelkar, AH, Dijk, SW, Feldman, ZM, Ward, ZJ, Moschini, M, Cathomas, R, Bellmunt, J, Gallioli, A, Breda, A, Fankhauser, CD, Mattei, A, Chang, SL, Siebert, U. Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysis. WORLD JOURNAL OF UROLOGY. 2025; 43(1)DOI:10.1007/s00345-025-05584-7. PMID:40159560. IF:2.900(Q2/3D).
29/03/2025
The Spanish GIRO Guideline: A Paradigm Shift in the Management of Obesity in Adults
Lecube, A, Azriel, S, Barreiro, E, Blay, G, Carretero-Gómez, J, Ciudin, A, Fernández, JM, Flores, L, de Hollanda, A, Martínez, E, Miñambres, I, Moizé, V, Morales, C, Ramírez, V, Salvador, J, Soler, MJ, Supervía, M, Valenti, V, Vicente-Rodríguez, G, Vilarrasa, N, Malagón, MM. The Spanish GIRO Guideline: A Paradigm Shift in the Management of Obesity in Adults. Obesity Facts. 2025; 18(4)DOI:10.1159/000544880. PMID:40159422. IF:4.700(Q1/2D).
28/03/2025
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment
Martinez-Molina, C, Vidal, S, Diaz-Torne, C, Park, HS, Corominas, H. Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment. Frontiers in Medicine. 2025; 12DOI:10.3389/fmed.2025.1512501. PMID:40224626. IF:3.000(Q1/2D).
28/03/2025
Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC
Borque-Fernando, A, Alonso-Gordoa, T, Juan-Fita, MJ, Campos, FL, Pérez-Fentes, DA, Vilaseca, A, Agut, CM, Usán, P, Rey, PM. Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. Future Oncology. 2025; 21(8)DOI:10.1080/14796694.2025.2468569. PMID:40029138. IF:2.600(Q3/6D).
27/03/2025
Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome: A Horizon 21 European Down syndrome Consortium study
Ivain, P, Baksh, A, Saini, F, Idris, M, Tamayo-Elizalde, M, Wells, J, Benejam, B, Loosli, SV, Sandkühle, K, Wlasich, E, Wagemann, O, Levin, J, Martet, D, Sacco, S, Falquero, S, Clert, M, Rebillat, AS, Khoo, WM, Smith, MA, Beresford-Webb, J, Zaman, S, Carmona-Iragui, M, Videla, L, Fortea, J, Langballe, EM, Medboen, IT, Larsen, FK, Baldimtsi, E, Paradisi, R, Ntailakis, P, Tsolaki, M, Papantoniou, G, Mcglinchey, E, Mccarron, M, Kennelly, S, Strydom, A. Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome: A Horizon 21 European Down syndrome Consortium study. ALZHEIMERS & DEMENTIA. 2025; 21(3)DOI:10.1002/alz.70071. PMID:40145416. IF:11.100(Q1/1D).
26/03/2025
Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA
Tibau, A, Hwang, TJ, Romano, A, Borrell, M, Gich, I, Molto, C, Kesselheim, AS. Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA. JAMA Network Open. 2025; 8(3)DOI:10.1001/jamanetworkopen.2025.2026. PMID:40136298. IF:9.700(Q1/1D).
26/03/2025
Strategy for drug repurposing in fibroadipogenic replacement during muscle wasting: application to duchenne muscular dystrophy
Matthews, I, Mehra, P, Suárez-Calvet, X, Piñol-Jurado, P, Cox, D, Justian, V, Carrasco-Rozas, A, Laidler, Z, Bowey, A, Rushton, P, López-Fernández, S, Díaz-Manera, J, Fernández-Simón, E. Strategy for drug repurposing in fibroadipogenic replacement during muscle wasting: application to duchenne muscular dystrophy. Frontiers in Cell and Developmental Biology. 2025; 13DOI:10.3389/fcell.2025.1505697. PMID:40206397. IF:4.300(Q1/1D).
25/03/2025
Use of Bayesian approaches in oncology clinical trials: A cross-sectional analysis
Lopez-Rey, BG, Carot-Sans, G, Ouchi, D, Torres, F, Pontes, C. Use of Bayesian approaches in oncology clinical trials: A cross-sectional analysis. Frontiers in Pharmacology. 2025; 16DOI:10.3389/fphar.2025.1548997. PMID:40201693. IF:4.800(Q1/2D).
25/03/2025
Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral Sclerosis
Mondesert, E, Delaby, C, de la Cruz, E, Kuhle, J, Benkert, P, Pradeilles, N, Duchiron, M, Morchikh, M, Camu, W, Cristol, JP, Hirtz, C, Esselin, F, Lehmann, S. Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral Sclerosis. NEUROLOGY. 2025; 104(6)DOI:10.1212/WNL.0000000000213400. PMID:40009787. IF:8.500(Q1/1D).
25/03/2025
Can ICD Electrograms Help Ventricular Tachycardia Ablation? Results From the Multicenter Randomized AIDEG-VTA Trial
Criado, JLI, Ortiz, M, García-Fernández, J, Martínez-Alday, JD, Font, ER, Moreno, J, López, MA, Almor, JM, Gil, ML, Medina, DG, Granell, RR, Peinado, RP, Gelizo, VB, Muñoz, JJS, Medina, O, Díaz-Parreño, SA, Criado, AI, Gonzalez, JM, Merodio, JMO, Almendral, J. Can ICD Electrograms Help Ventricular Tachycardia Ablation? Results From the Multicenter Randomized AIDEG-VTA Trial. JACC-JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2025; 85(11)DOI:10.1016/j.jacc.2024.10.104. PMID:39772368. IF:22.300(Q1/1D).
25/03/2025
Inositol 1,4,5-Trisphosphate Receptor 1 Gain-of-Function Increases the Risk for Cardiac Arrhythmias in Mice and Humans
Sun, B, Ni, MK, Li, YH, Song, ZP, Wang, H, Zhu, HL, Wei, JH, Belke, D, Cai, ST, Guo, WT, Yao, JJ, Tian, SS, Estillore, JP, Wang, RW, Sondergaard, MT, Brohus, M, Rohde, PD, Mu, YX, Vallmitjana, A, Benitez, R, Hove-Madsen, L, Overgaard, MT, Fishman, GI, Chen, J, Sanatani, S, Wilde, AAM, Fill, M, Ramos-Franco, J, Nyegaard, M, Chen, SRW. Inositol 1,4,5-Trisphosphate Receptor 1 Gain-of-Function Increases the Risk for Cardiac Arrhythmias in Mice and Humans. CIRCULATION. 2025; 151(12)DOI:10.1161/CIRCULATIONAHA.124.070563. PMID:39655431. IF:38.600(Q1/1D).
25/03/2025
Decreased practice effects in cognitively unimpaired amyloid betapositive individuals: a multicenter, longitudinal, cohort study
Tort-Merino, A, Pérez-Millan, A, Falgàs, N, Borrego-ecija, S, Esteller, D, Bosch, B, Castellví, M, Juncà-Parella, J, del Val-Guardiola, A, Fernández-Villullas, G, Antonell, A, Sanchez-Saudinós, MB, Rubio-Guerra, S, Zhu, NL, García-Martínez, M, Pozueta, A, Estanga, A, Ecay-Torres, M, de Luis, CL, Tainta, M, Altuna, M, Rodríguez-Rodríguez, E, Sánchez-Juan, P, Martínez-Lage, P, Lleó, A, Fortea, J, Illán-Gala, I, Balasa, M, Lladó, A, Rami, L, Sánchez-Valle, R. Decreased practice effects in cognitively unimpaired amyloid betapositive individuals: a multicenter, longitudinal, cohort study. ALZHEIMERS & DEMENTIA. 2025; 21(3)DOI:10.1002/alz.70016. PMID:40133248. IF:11.100(Q1/1D).
24/03/2025
Potential of facial biomarkers for Alzheimer's disease and obstructive sleep apnea in Down syndrome and general population
Echeverry-Quiceno, LM, Llambrich, S, Heredia-Lidón, A, Giménez, S, Rozalem-Aranha, M, Inampudi, P, Heuzé, Y, Sevillano, X, Fortea, J, Martinez-Abadias, N, Alzheimers Dis Neuroimaging Initiative. Potential of facial biomarkers for Alzheimer's disease and obstructive sleep apnea in Down syndrome and general population. FASEB JOURNAL. 2025; 39(6)DOI:10.1096/fj.202403009R. PMID:40123509. IF:4.200(Q1/2D).